Acuta Capital Partners, LLC Altimmune, Inc. Transaction History

Acuta Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $1.33 Million - $2.8 Million	125,000 New	125,000 $1.6 Million
Q4 2021 Feb 14, 2022	SELL	$8.69 - $12.48 $1.3 Million - $1.87 Million	-150,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$8.43 - $16.81 $1.26 Million - $2.52 Million	150,000 New	150,000 $1.7 Million
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $4.01 Million - $6.7 Million	-407,055 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$12.71 - $24.31 $2.18 Million - $4.17 Million	-171,445 Reduced 29.64%	407,055 $5.75 Million
Q4 2020 Feb 16, 2021	SELL	$7.84 - $14.22 $858,480 - $1.56 Million	-109,500 Reduced 15.92%	578,500 $6.53 Million
Q3 2020 Nov 16, 2020	BUY	$9.93 - $33.26 $1.49 Million - $5.01 Million	150,500 Added 28.0%	688,000 $9.08 Million
Q2 2020 Aug 14, 2020	BUY	$2.9 - $10.71 $1.56 Million - $5.76 Million	537,500 New	537,500 $5.76 Million

186

39.4M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $329M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.